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ABSTRACT  
Objective:  
 To estimate the effectiveness of first-line biologic disease modifying drugs(boDMARDs), and their approved 
biosimilars (bsDMARDs), compared to conventional (csDMARD) treatment,  in terms of ACR (American College 
of Rheumatology) and EULAR (European League against Rheumatism) responses.  
Methods: 
Systematic literature search, on eight databases to January 2017, sought ACR and EULAR data from 
randomised controlled trials (RCTs) of boDMARDs / bsDMARDs (in combination with csDMARDs, or 
monotherapy). Two adult populations: methotrexate (MTX)-naïve patients with severe active RA; and 
csDMARD-experienced patients with moderate-to-severe active RA. Network meta-analyses (NMA) were 
conducted using a Bayesian Markov chain Monte Carlo simulation using a random effects model with a probit 
link function for ordered categorical. 
Results: 
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Forty-six RCTs met the eligibility criteria. In the MTX-naïve severe active RA population, no biosimilar trials 
meeting the inclusion criteria were identified. MTX plus methylprednisolone (MP) was most likely to achieve 
the best ACR response. There was insufficient evidence that combination boDMARDs was superior to intensive 
(two or more) csDMARDs. In the csDMARD-experienced, moderate-to-severe RA population, the greatest 
effects for ACR responses were associated with tocilizumab (TCZ) monotherapy, and combination therapy 
(plus MTX) with bsDMARD etanercept (ETN) SB4, boDMARD ETN and TCZ. These treatments also had the 
greatest effects on EULAR responses. No clear differences were found between the boDMARDs and their 
bsDMARDs. 
Conclusion: 
In MTX-naïve patients, there was insufficient evidence that combination boDMARDs was superior to two or 
more csDMARDs. In csDMARD-experienced patients, boDMARDs and bsDMARDs were comparable  and all 
combination boDMARDs / bsDMARDs were superior to single csDMARD.  
 
Keywords: rheumatoid arthritis, biological agents, biosimilar, , systematic review, network meta-analysis 
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The introduction of novel targeted therapies such as biologic original disease-modifying anti-rheumatic drugs 
(boDMARDs) has expanded the arsenal of available drugs for rheumatoid arthritis (RA). These are usually 
prescribed on failure of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 
Biosimilars (bsDMARDs) of boDMARDs have recently been approved by the European Medicines Agency 
(EMA). The introduction of bsDMARDs onto the market may have the potential to provide a cheaper 
alternative to boDMARDs, provided they have similar effectiveness. 
There are a wide range of treatment options offered, and few head-to-head randomised controlled trials 
(RCTs) between boDMARDs and bsDMARDs. A network meta-analysis allows a synthesis of all available 
evidence  
In 2017, the French national authority for health (Haute Autorité de Santé, HAS) initiated an economic 
evaluation of biological treatments for RA in csDMARD-experienced and MTX-naïve populations. The rationale 
of that evaluation emphasised two issues: 
x boDMARDs place a substantial financial burden on healthcare systems and individual patients. The 
overall costs of boDMARDs should take into account the benefit of reducing the disease impact, 
however research is required to fully assess differences in cost-effectiveness between the currently 
available treatments 
x A wide range of treatment options is offered, and there are few head-to-head randomised controlled 
trials (RCTs) between boDMARDs and bsDMARDs. A network meta-analysis can provide useful 
comparative evidence in order to define the best treatment strategies and a simultaneous 
comparison between treatments.  
Unlike other reviews of biologics in RA, the current review included licensed bsDMARDs and boDMARDs 
compared with csDMARD therapy, and considered MTX-naive and csDMARD-experienced populations 
separately. Our study focused on the effectiveness criteria and aimed to estimate the short-term comparative 
effectiveness, on American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 
responses, of first-line boDMARDs, and their EMA approved biosimilars. The choice of these outcomes was 
validated by the HAS clinical experts of the RA economic evaluation.  Analysis of the safety outcomes were 
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beyond the scope of this study.  This will be proposed in an independent chapter of the HAS on-going cost 
effectiveness report 
 
MATERIALS AND METHODS 
The review was conducted in accordance with the general principles recommended in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. (1) The review was an update of work 
by Stevenson et al 2016. (2) 
Data sources 
The following electronic bibliographic databases were searched: Medline and Medline in Process (via Ovid SP); 
Embase (via Ovid SP); Cochrane Database of Systematic Reviews (via Wiley); Cochrane Central Register of 
Controlled Trials (via Wiley); Health Technology Assessment Database (via Wiley); Database of Abstracts of 
Reviews of Effect (via Wiley); CINAHL (via EBSCOhost); and Toxline (via ProQuest). Original searches were 
performed on the databases from inception until May 2013 (2) and the searches were updated on 23
rd
 January 
2017. The exact search strategies are available from the authors. Electronic database searches were 
supplemented with searching of bibliographies of included trials, and information provided by trial authors. 
 
 
Trial selection 
Study design was restricted to RCTs. Two populations of adult RA patients were included: a MTX-naïve 
ƉŽƉƵůĂƚŝŽŶ ǁŝƚŚ ƐĞǀĞƌĞ ĂĐƚŝǀĞ Z  ?^ ? ?A? ? ? ? ? ? ĂŶĚ ĂĚƵůƚƐ ǁŝƚŚ ŵŽĚĞƌĂƚĞ ƚŽ ƐĞǀĞƌĞ ĂĐƚŝǀĞ Z  ?^ ? ?A? ? ? ? ?
previously treated with, and inadequately responded to, csDMARDs (a csDMARD-experienced population). 
csDMARDs included methotrexate, sulfasalazine, leflunomide, with methotrexate being most commonly used. 
The following boDMARDs and bsDMARDs were included, as first-line biologic treatment, prescribed in 
accordance with EMA licensed indications: abatacept (ABT); adalimumab (ADA); certolizumab pegol (CTZ); 
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etanercept (ETN) and its biosimilar SB4 (Benepali); golimumab (GOL); infliximab (IFX) and its biosimilars CT-P13 
(Inflectra or Remsima) and SB2 (Flixabi); and tocilizumab (TCZ). Following the date of our searches, biosimilars 
of adalimumab (Amgevita, Cyltezo, Imraldi, Solymbic) have been approved, however as these were not 
licensed at the time of searches they were not included. boDMARDs and bsDMARDs could be delivered either 
as monotherapy (as allowed by current French licensed indications), or in combination with csDMARDs 
(biologic plus csDMARD combination therapy is illustrated by + in Tables and Figures).  
Included comparators were boDMARDs or bsDMARDs compared with each other, single csDMARD treatment, 
or intensive csDMARDs (two or more csDMARDs). Additionally, for the MTX-naïve population, management 
strategies involving further conventional DMARDs (e.g. SSZ, LEF), NSAIDs and corticosteroids. The outcomes 
sought were ACR responses or EULAR responses at follow-up between 22 weeks and 30 weeks. RCTs with early 
escape were only included if they reported a non-responder imputation. Two reviewers independently 
selected trials based on the review inclusion criteria, with any discrepancy resolved by a third reviewer. 
Data collection and assessment of bias 
One reviewer extracted data, and these data were checked by a second reviewer. Study arms where 
intervention treatments were administered in line with licensed indications were extracted. Where studies had 
treatment arms with unlicensed doses, these were not extracted. Two reviewers independently performed 
quality assessment based on the 2011 Cochrane risk of bias tool criteria 1.0. (3)  Data extraction and quality 
assessment forms developed in Stevenson et al (2) were used. Any discrepancy was resolved by a third 
reviewer. 
Network meta-analysis  
Network meta-analyses (NMAs) of ACR and EULAR data at 22-30 weeks follow-up were conducted using 
Bayesian Markov chain Monte Carlo (MCMC) simulation. ACR and EULAR data were analysed as ordered 
categorical data with mutually exclusive categories: ACR has four ordered categories (no response, ACR20, 
ACR50 and ACR70) and EULAR has three categories (no response, moderate response and good response). 
Data were analysed using a probit link function(4) a random effects model to allow for heterogeneity in 
treatment effects across studies and assuming an homogeneous variance. Inconsistency between direct and 
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indirect evidence was assessed using a node-splitting method.(4)  The reference treatment was defined as any 
single csDMARD (mostly MTX).  This choice was approved by the clinical experts involved in the HAS economic 
evaluation of boDMARDs strategies.  Meta-regression was performed to explore whether duration of disease 
was a treatment effect modifier. Absolute goodness-of-fit of the model was assessed using residual deviance. 
The analyses assumed that biosimilar treatments were not the same as their parent treatment. All the analyses 
were performed in OpenBUGS using the R package R2OpenBUGS.(5)  For each analysis, the first 180,000 
iterations were discarded to allow for the number of iterations required for convergence to the target 
distribution, and 20,000 further iterations were used to estimate parameters. Convergence to the target 
distribution were checked using Gelman Rubin diagnostics.(6)  The most effective treatment was determined 
by the probability of being ranked as the best treatment, which considered the size of the treatment effect and 
its associated uncertainty. 
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RESULTS 
Included trials 
The electronic database search identified 34,621 records and bibliography searching identified an additional 18 
records. Following title and abstract sifting, 128 studies were assessed for eligibility, and 82 studies excluded 
(see Supplementary Figure S1 PRISMA flow diagram(1) for reasons for exclusion). Of the 17 trials excluded for 
not reporting ACR or EULAR responses within 22-30 weeks follow-up: 12 were trials with randomised phases 
ƐŚŽƌƚĞƌƚŚĂŶ ? ?ǁĞĞŬƐ ?ŝŶŽŶĞZdƉĂƌƚŝĐŝƉĂŶƚƐŝŶĞŝƚŚĞƌĂƌŵĐŽƵůĚƌĞĐĞŝǀĞĂĚĚŝƚŝŽŶĂůƚƌĞĂƚŵĞŶƚĂƚĐůŝŶŝĐŝĂŶ ?Ɛ
discretion after three months; two had unlicensed comparators; one reported EULAR Boolean 28 at 1 year 
follow-up, but did not report ACR or EULAR responses; and one had the primary endpoint of safety and 
measured efficacy as the secondary endpoints of DAS44 and the health assessment questionnaire." 
There were 46 trials meeting the review inclusion criteria, comprising ten RCTs(7-16) with a MTX-naïve 
population, and 36 RCTs(17-52) with a csDMARD-experienced population. Included trials are shown in Table 1. 
There was a balance across trials in terms of population characteristics and trial quality. There was some 
variation between trials in disease duration (Table 1), with the MTX-naïve population ranging from 5-166 
weeks, and csDMARD-experienced ranging from 94-676 weeks. However, meta-regression suggested that 
disease duration was not a treatment effect modifier for ACR response, with the estimated coefficient of the 
disease duration being close to zero. The limited number of RCTs did not allow us to perform meta-regression 
including disease duration for EULAR response in the two selected populations. We found no evidence of 
selective outcome reporting in the included trials. There was a low risk of bias in terms of blinding and analyses 
(Supplementary Figure S2). The majority of RCTs were blinded (74%), and reported analyses with either intent-
to-treat or modified intent-to-treat (that is, all randomised patients who received at least one dose of trial 
drug were included in the analyses, 87% of RCTs). There was a higher risk of bias regarding randomisation, with 
unclear reporting of sequence generation and allocation concealment (54% and 52% of RCTs respectively). 
Network meta-analyses 
ACR response data were provided by ten trials of the MTX-naïve population, and thirty-four trials of the 
csDMARD-experienced population (Table 1). EULAR response data were provided by two trials of the MTX-
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naïve population and nineteen trials of the csDMARD-experienced population (Table 1). Network diagrams are 
shown in Supplementary Figure S3. Results are presented using medians and 95% credible intervals (CrI) from 
posterior distributions, treatment rankings. The probabilities of being the best treatment were calculated for 
each analysis. The models fitted the data well with the total residual deviance close to the total number of 
data points.  
ACR responses 
Figure 1 shows the NMA for ACR responses. Results shown are the effect of each treatment relative to 
csDMARD on the probit scale, with negative values representing positive treatment effects (i.e. a smaller 
proportion of patients in the lower ACR categories). 
In the MTX-naïve population, all treatments, except ADA monotherapy, were associated with beneficial 
median treatment effects relative to csDMARD with the greatest effect being associated with MTX plus MP 
(effect on probit scale -0.79, 95% CrI: -1.44 to -0.20) and IFX+(-0.74, 95% CrI: -1.14, -0.40). However, the 
treatment effects were superior against csDMARDs only for ADA+, ETN+, IFX+, intensive cDMARDs (two or 
more csDMARDs) and MTX plus MP at a conventional 5% level (Figure 1). Intensive cDMARDs and boDMARDs 
had similar responses. The difference between intensive csDMARDs and boDMARDs was not significant (data 
not shown). MTX plus MP was most likely to be the most effective intervention (median rank 1; probability of 
being the best 0.51). The estimated between-trial standard deviation was 0.10 (95% CrI: 0.02 to 0.34). 
In the csDMARD-experienced population, all treatments, except placebo, were associated with beneficial 
median treatment effect relative to csDMARD with the greatest effects being associated with bsDMARD ETN 
(SB4)+ (-1.12, 95% CrI: -1.70 to -0.55), boDMARD ETN+ (-0.03, 95% CrI: -1.34 to -0.73),  TCZ+ (-1.08, 95% CrI: -
1.43 to -0.73) and TCZ monotherapy (-1.08, 95% CrI: -1.39 to -0.76)). The treatment effects were superior 
compared to csDMARD for all interventions except for ADA (borderline non-statistically significant) at a 
conventional 5% level (Figure 1). The treatment that was most likely to be the best was the bsDMARD of ETN 
(SB4) combination therapy (median rank 2; probability of being the best 0.37). The estimated between-trial 
standard deviation was 0.22 (95% CrI: 0.12 to 0.35). 
EULAR responses 
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Figure 2 shows the NMA for EULAR responses. Results shown are the effect of each intervention relative to 
csDMARDs on the probit scale, with negative values representing positive treatment. 
Only two trials provided EULAR response data in the MTX-naïve population. The results showed that ADA+ and 
GOL+ were associated with beneficial treatment effects relative to csDMARD with the greatest effect being 
associated with ADA+ (-0.64, 95% CrI: -1.15 to -0.15). However, the treatment effect was superior only for 
ADA+ at a conventional 5% level (Figure 2). ADA+ was most likely to be the most effective intervention of the 
three interventions with EULAR response data (ADA+, GOL+ and csDMARD) (median rank 1; probability of 
being the best 0.84). The estimated between-trial standard deviation was 0.14 (95% CrI: 0.03 to 0.48). 
However, this was based on only two trials. 
In the csDMARD-experienced population, all treatments, except placebo, were associated with beneficial 
median treatment effects relative to csDMARD with the greatest effect being associated with TCZ+(-1.56, 95% 
CrI: -2.21 to -1.01), TCZ monotherapy (-1.47, 95% CrI: -2.15 to -0.89), ETN+ (-1.34, 95% CrI: -2.55 to -0.14) and 
bsDMARD ETN (SB4)+ (-1.36, 95% CrI: -2.78 to 0.05). The treatment effects were superior only for ETN+, GOL+, 
IFX+, CTZ+, TCZ (with and without MTX) at a conventional 5% level (Figure 2). The effects of combination 
therapies of bsDMARDs were comparable to boDMARDs (data not shown, available from authors on request). 
TCZ+ was the treatment that was most likely to be the most effective intervention (median rank 2; probability 
of being the best 0.33) for EULAR responses. The estimated between-trial standard deviation was 0.34 (95% 
CrI: 0.15 to 0.53). 
DISCUSSION 
In this review of ten RCTs, we found that in the MTX-naïve population, MTX plus MP, or intensive csDMARDs 
(that is, two or more csDMARDs), were comparable to boDMARD treatment for ACR responses. Thirty-six RCTs 
contributed data to NMAs of the csDMARD-experienced population. For both ACR and EULAR responses in this 
population, the greatest effects were associated with combination therapy (with MTX) of bsDMARD ETN, 
boDMARD ETN and TCZ, as well as TCZ monotherapy. The effects of combination therapies of bsDMARDs were 
comparable to boDMARDs (data not shown, available from authors on request). The ongoing results of the 
French economic evaluation of biologic treatments sequences for moderately-to-severely active RA should 
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confirm whether bsDMARDs strategies instead of boDMARDs for a csDMARD-experienced patients are cost-
effective option. However, concerning the MTX-naïve patients, the above results that showed comparable 
effect between boDMARDs and intensive cDMARDs at six months seem in line with the recent RA French 
guidelines which do not recommend to reimburse the use of biological treatments for this indication (except 
when MTX is contraindicated).  
One of the strengths of our study was to adopt strict definitions of outcomes and populations that are both 
consistent with the therapeutic strategies of RA (as they are defined by EULAR and ACR) and the existing 
indications in the RA French management. 
Our approach was different from other NMAs performed by HTA institutions (e.g. CADTH, 2018; (53) ICER, 
2017) (54) or Cochrane  of biologics (e.g. Singh et al, 2016; (55) Singh et al, 2017 (56) Hazlewood et al, 2016) 
(57) who included many outcomes (e.g. DAS28, remission, radiographic progression) but did not use EULAR 
criterion. Moreover, the analysed population were not often the same as the CADTH (2018) (53)  and ICER 
(2017) (54)  who focused only on clinical effectiveness for moderately-to-severely active RA for patients who 
had an inadequate response to prior csDMARDs. 
Despite many differences in terms of exclusion criteria, inclusion of targeted synthetic DMARD (e.g. baricitinib 
and tofactinib) and the number of analysed studies, our findings on ACR criterion (e.g. ACR50) comparing 
boDMARDs showed similar findings for moderately-to-severely active RA as the above NMAs: most of 
boDMARDs (and bsDMARDs) compared with cDMARDs (i.e. MTX) showed a clinical benefit but they did not 
often allow to detect a significant difference when compared with each other.  
Concerning MTX-naïve patients, our results were partially similar with those of Singh et al (2017) (56) that 
showed  that biologic with MTX were associated with statistically benefits in terms of achievement of ACR50:  
In our analysis, boDMARDs (IFX+MTX, ETN+MTX, ADA+MTX) as well as  intensive cDMARDs and MTX+ MP were 
more effective than cDMARDs. 
 
The review had limitations. The searches were conducted in 2017. There was limited evidence on EULAR 
response in MTX-naïve patients, with no bsDMARD RCTs meeting the inclusion criteria of the review, and no 
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data for MTX plus MP or intensive csDMARDs for EULAR response. The limited number of RCTs did not allow us 
to perform meta-regression including disease duration for EULAR response. Only three RCTs of bsDMARDs 
meeting the inclusion criteria were identified. As bsDMARDs were compared only to their boDMARD, their 
inclusion in the NMA did not affect the results for other inventions since they did not form a closed loop in the 
network. Ideally, evidence synthesis based on remission or low disease activity would be used as these are 
established treatment targets and routinely used for monitoring patients in European clinical practice. The 
EMA guidelines consider that remission should be the primary endpoint in clinical trials, and can be either 
defined according to EULAR criteria (DAS28<2.6), or in accordance with the more strict EULAR ?ACR criteria 
(Boolean or Index-based).(58) Nevertheless, there are few data in the RCTs on this criterion to make relevant 
comparisons, and so we compared the treatments on the ACR criteria, and the EULAR response, instead as 
these scores represent a relative change from baseline. 
Our review included trials of bsDMARDs, while the majority of previous reviews have included only anti-TNF 
biologics. Our review differed from other reviews of biologics in RA, in that i) it was limited to first-line 
biologics; ii) it considered MTX-naive and csDMARD-experienced trials separately; iii) it was limited to trials 
reporting outcomes at 22-30 weeks follow-up; iv) it considered ACR and EULAR as ordered categorical data, 
whereas the reviews by Hazlewood et al. (2016) (57)  Singh et al, 2016, (55), Singh et al, 2017 (56) and CADTH 
(2018) (53) treated these outcomes as binary which ignores the natural ordering and correlation between 
categories. Treating patient responses as mutually exclusive categories enables a simultaneous analysis of the 
data, including studies that do not provide information about some categories, and a single estimate of 
treatment effect.    
The finding that intensive csDMARDs were comparable to boDMARDs for MTX-naïve patients (data not shown) 
also agreed with a previous review. (57) Previous meta-analyses underscored the dearth of direct evidence of 
effectiveness difference between biological agents. (59, 60) Our findings suggested that TCZ monotherapy was 
most favourable for csDMARD-experienced RA patients. This result was coherent with the conclusions of a 
previous review(61) where TCZ was either of comparable or superior efficacy to other boDMARDs. However, 
this finding might be explained by the fact that, for boDMARDs with a significant effect toward inhibition of 
acute phase reactants (APR), such as TCZ or the Janus kinase inhibitors, DAS28 may overestimate clinical 
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response due to the high weight of APR components in the DAS28 formula. (62) Similarly CRP level is a 
component of ACR response. It is commented that there may be silent residual inflammation in the joints even 
though CRP is low.  
In clinical practice, decision making in patients with RA is not the same as in clinical trials. The choice of 
treatment is the result of a complex decision process that must take into account disease activity, and 
physician and patient characteristics.   For triple intensive csDMARD therapy, despite the efficacy, the question 
of treatment adherence and persistence remain.  
CONCLUSION 
Our findings provide data for the short term effectiveness of boDMARDs and bsDMARDs for use in the current 
HAS economic evaluation of DMARD stratĞŐŝĞƐĨŽƌZ ?ĚǀĞƌƐĞĞǀĞŶƚƐǁĞƌĞŶŽƚĂĚĚƌĞƐƐĞĚ ?ďƵƚǁĞƌĞŝŶ,^ ?Ɛ
economic decision model. 
For MTX-naïve patients with severe active RA, MTX plus MP or intensive csDMARDs, at six months, were 
comparable to boDMARDs, with all these treatments being superior to a single csDMARD. For csDMARD-
experienced patients with moderate to severe active RA, bsDMARDs were comparable to their boDMARD. 
Combination therapy with all boDMARDs and bsDMARDs were superior to csDMARD treatment, with 
bsDMARD ETN, boDMARD ETN, and TCZ likely to be the most effective.  
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